Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00002429

Recruitment Status : Completed

First Posted : August 31, 2001

Last Update Posted : May 4, 2011

Sponsor:

Information provided by:

Bristol-Myers Squibb

Study Description

Brief Summary:

This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach before dissolving. The purpose of this study is to compare the effectiveness of an anti-HIV drug combination that includes ddI EC versus another anti-HIV drug combination.

Condition or disease	Intervention/treatment	Phase
HIV Infections	Drug: Lamivudine/Zidovudine Drug: Nelfinavir mesylate Drug: Stavudine Drug: Didanosine	Phase 3

Detailed Description:

Patients are randomized to 1 of 2 groups for 48 weeks of open-label treatment. Group 1 receives ddI EC plus d4T plus NFV. Group 2 receives Combivir plus NFV. Antiviral activity is determined by the proportion of patients with HIV RNA levels of less than 400 copies/ml at Week 48.

Study Design


Study Type :	Interventional (Clinical Trial)
Enrollment :	500 participants
Intervention Model:	Parallel Assignment
Primary Purpose:	Treatment
Official Title:	Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen
Study Start Date :	July 1999
Actual Primary Completion Date :	January 2001
Actual Study Completion Date :	January 2001

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Didanosine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Are HIV-positive.
Have a viral load of at least 2,000 copies/ml and a CD4 count of at least 200 cells/mm3.
Are at least 18 years old.
Agree to practice sexual abstinence or to use effective barrier methods of birth control (such as condoms).

Exclusion Criteria

Patients will not be eligible for this study if they:

Have had severe diarrhea within 30 days of study entry.
Have a history of pancreatic disease or any other serious condition.
Have hepatitis within 30 days of study entry.
Are diagnosed with an opportunistic (AIDS-related) infection at the time of enrollment.
Are unable to take medications by mouth.
Have received certain medications.
Are pregnant or breast-feeding.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002429

Show 23 Study Locations

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators


Study Director:	Bristol-Myers Squibb	Bristol-Myers Squibb

More Information

Additional Information:

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Publications:

Gathe J, Badero R, Grimwood A, Abrams L, Klesczewski K, Mclaren C. AI454152: Comparison of a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine Administered Once-Daily Versus a Regimen of Combivir Plus Nelfinavir. 8th Conference on Retroviruses and Opportunistic Infections, 2001 Feb 4-8. (abstract no 319)


ClinicalTrials.gov Identifier:	NCT00002429 History of Changes
Other Study ID Numbers:	039F AI454-152
First Posted:	August 31, 2001 Key Record Dates
Last Update Posted:	May 4, 2011
Last Verified:	April 2011

Keywords provided by Bristol-Myers Squibb:


Didanosine Drug Therapy, Combination Stavudine RNA, Viral	Nelfinavir Reverse Transcriptase Inhibitors Anti-HIV Agents

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Lamivudine Zidovudine Stavudine Didanosine	Lamivudine, zidovudine drug combination Nelfinavir Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Anti-HIV Agents Antimetabolites HIV Protease Inhibitors Protease Inhibitors

To Top